

1 **Generalisable functional imaging classifiers of schizophrenia have multifunctionality as**
2 **trait, state, and staging biomarkers**

3

4 Running title: Functional imaging classifiers of schizophrenia

5

6 **Authors:**

7 Takahiko Kawashima, MD^{1†*}, Ayumu Yamashita, PhD^{2,3†}, Yujiro Yoshihara, MD, PhD¹, Yuko

8 Kobayashi, MD¹, Naohiro Okada, MD, PhD^{4,5}, Kiyoto Kasai, MD, PhD^{4,5,6}, Ming-Chyi

9 Huang, MD, PhD^{7,8}, Akira Sawa, MD, PhD^{9,10,11,12,13,14}, Junichiro Yoshimoto, PhD^{2,15,16},

10 Okito Yamashita, PhD^{2,17}, Toshiya Murai, MD, PhD¹, Jun Miyata, MD, PhD^{1,18}, Mitsuo

11 Kawato, PhD^{2,19*}, and Hidehiko Takahashi, MD, PhD^{1,20,21*}

12 **Affiliations:**

13 ¹Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan

14 ²Brain Information Communication Research Laboratory Group, Advanced

15 Telecommunications Research Institute International, Kyoto, Japan

16 ³Graduate School of Information Science and Technology, The University of Tokyo, Tokyo,

17 Japan

18 ⁴Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo,

1 Tokyo, Japan

2 ⁵The International Research Centre for Neurointelligence (WPI-IRCN) at The University of

3 Tokyo Institutes for Advanced Study (UTIAS), The University of Tokyo, Tokyo, Japan

4 ⁶UTokyo Institute for Diversity and Adaptation of Human Mind (UTIDAHM), The

5 University of Tokyo, Tokyo, Japan

6 ⁷Department of Addiction Sciences, Taipei City Psychiatric Center, Taipei City Hospital,

7 Taipei, Taiwan

8 ⁸Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical

9 University, Taipei, Taiwan

10 ⁹Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD,

11 USA

12 ¹⁰Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore,

13 MD, USA

14 ¹¹Department of Biomedical Engineering, Johns Hopkins University School of Medicine,

15 Baltimore, MD, USA

16 ¹²Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore,

17 MD, USA

1 ¹³Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore,

2 MD, USA

3 ¹⁴Department of Mental Health, Johns Hopkins Bloomberg School of Public Health,

4 Baltimore, MD, USA

5 ¹⁵ Department of Biomedical Data Science, Fujita Health University School of Medicine,

6 Toyoake, Japan

7 ¹⁶International Centre for Brain Science (ICBS), Fujita Health University, Toyoake, Japan

8 ¹⁷RIKEN, Centre for Advanced Intelligence Project, Tokyo, Japan

9 ¹⁸Department of Psychiatry, Aichi Medical University, Nagakute, Japan

10 ¹⁹XNef Incorporation, Kyoto, Japan

11 ²⁰Department of Psychiatry and Behavioural Sciences, Graduate School of Medical and

12 Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

13 ²¹Centre for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan

14 †These authors contributed equally to this work.

15 *Corresponding authors:

1 Takahiko Kawashima

2 Address: 6th floor, North ward building, Kyoto University Hospital, 54

3 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan

4 Phone: +81-75-751-4947

5 Fax: +81-75-751-3378

6 E-mail: tkawashima@kuhp.kyoto-u.ac.jp

7 Mitsuo Kawato

8 Address: 2-2-2 Hidaridai, Seika-cho, Souraku-gun, Kyoto 619-0288, Japan

9 Phone: +81-774-95-1058

10 Fax: +81-774-95-1236

11 E-mail: kawato@atr.jp

12 Hidehiko Takahashi

13 Address: 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

14 Phone: +81-3-5803-5238

15 Fax: +81-3-5803-0135

16 E-mail: hidepsyc@tmd.ac.jp

1 **ABSTRACT**

2 Schizophrenia spectrum disorder (SSD) is one of the top causes of disease burden; similar to
3 other psychiatric disorders, SSD lacks widely applicable and objective biomarkers. This study
4 aimed to introduce a novel resting-state functional connectivity (rs-FC) magnetic resonance
5 imaging (MRI) biomarker for diagnosing SSD. It was developed using customised machine
6 learning on an anterogradely and retrogradely harmonised dataset from multiple sites,
7 including 617 healthy controls and 116 patients with SSD. Unlike previous rs-FC MRI
8 biomarkers, this new biomarker demonstrated a notable accuracy rate of 77.3% in an
9 independent validation cohort, including 404 healthy controls and 198 patients with SSD from
10 seven different sites, effectively mitigating across-scan variability. Importantly, our biomarker
11 specifically identified SSD, differentiating it from other psychiatric disorders. Our analysis
12 identified 47 important FCs significant in SSD classification, several of which are involved in
13 SSD pathophysiology. Beyond their potential as trait markers, we explored the utility of these
14 FCs as both state and staging markers. First, based on aggregated FCs, we built prediction
15 models for clinical scales of trait and/or state. Thus, we successfully predicted delusional
16 inventory scores ($r=0.331$, $P=0.0177$), but not the overall symptom severity ($r=0.128$,
17 $P=0.178$). Second, through comprehensive analysis, we uncovered associations between
18 individual FCs and symptom scale scores or disease stages, presenting promising candidate
19 FCs for state or staging markers. This study underscores the potential of rs-FC as a clinically
20 applicable neural phenotype marker for SSD and provides actionable targets to
21 neuromodulation therapies.

1 INTRODUCTION

2 Diagnosis of schizophrenia spectrum disorder (SSD) relies on diagnostic criteria that
3 categorise disorders based solely on signs and symptoms. There are currently no widely
4 applicable objective biomarkers¹ that can distinguish individuals with SSD from their healthy
5 counterparts.

6 Generating an SSD classifier using resting-state functional connectivity (rs-FC)
7 magnetic resonance imaging (MRI) is an emerging research topic. However, the practical use
8 of these classifiers is hindered by several key challenges²⁻⁵. First, there is an accuracy problem.
9 In studies with a large sample size and external validation^{6,7}, classifier performance was below
10 biomarker requirements (approximately 80%). Accuracy typically decreases with increase in
11 sample size ($N > 200$) in whole-brain imaging biomarkers⁸. A machine learning algorithm
12 requiring many explanatory variables (i.e. FCs) needs more data to achieve accuracy and
13 generalisability; however, large training samples from multiple facilities may cause a large site
14 effect, deteriorating data quality⁹. Second, there is an issue with generalisability. Most previous
15 studies have used only internal or limited external validation and lacked genuinely independent
16 cohorts obtained in multiple sites not involved in the initial research¹⁰. Third, across-session
17 variability poses a problem. The reliability of rs-fMRI is questionable over repeated tests¹¹.
18 Finally, there is a lack of specificity in potential biomarkers identified in rs-FC MRI studies
19 focusing on specific disorders. Overcoming these issues is crucial for determining truly
20 effective biomarkers for clinical use in SSD.

21 Although disease trait markers assist early intervention, state markers estimate
22 dynamic changes in response to treatment^{12,13} and staging markers aid disease prevention or
23 personalising interventions¹⁴. In SSD research, few studies have succeeded in developing state
24 markers using neuroimaging, and for staging markers, there is no consensus on biological

1 staging models¹⁵.

2 Patient biological data may simultaneously encompass information on traits, states,
3 and disease stages. As machine learning exploits these features without making distinctions,
4 diagnostic markers developed using machine learning may also function as state and/or staging
5 markers. Previous rs-FC biomarker studies reported multiple aggregated FCs as
6 biomarkers^{16,17}; however, whether individual FCs can be used as one or more of these three
7 types of biomarkers remains unexplored. A previous study showed that FCs originally
8 identified as diagnostic markers dynamically changed after treatment¹⁸; thus, they also
9 functioned as state markers. Nevertheless, thoroughly investigating individual FCs has not
10 been attempted, making it difficult to determine whether any FCs can benefit early disease
11 detection and intervention as a trait marker or treatment target selection and drug discovery as a
12 surrogate marker.

13 Our study focused on two key areas (**Figure 1**). First, we aimed to develop a clinically
14 viable rs-FC biomarker for SSD, addressing the challenges mentioned above. Second, we
15 aimed to investigate whether the diagnostic biomarker can be used as state and staging markers.
16 The findings of this study can help develop new approaches for improving the diagnosis and
17 treatment of various psychiatric disorders, not only SSD.

1 MATERIALS AND METHODS

2 Participants

3 We used two independent multi-disorder datasets: one for developing classifiers ('discovery
4 dataset') and the other for validating the classifiers ('validation dataset'). Participant
5 characteristics are presented in **Table 1** and **Supplementary Table 1**. There was no overlap of
6 participants between the discovery and validation datasets.

7 The discovery dataset comprised data from four sites: Kyoto University Siemens
8 TimTrio scanner, Showa University (SWA), Centre of Innovation in Hiroshima University, and
9 University of Tokyo (UTO). The dataset included 1 045 participants consisting of 617 healthy
10 controls (HCs), 116 patients with SSD (which includes schizophrenia, schizoaffective disorder,
11 and delusional disorder), 148 patients with major depressive disorder (MDD), 125 patients
12 with autism spectrum disorder (ASD), and 39 patients with bipolar disorder (BP).

13 The validation dataset comprised international cohorts, including the Japanese cohort
14 from Hiroshima Kajikawa Hospital, Hiroshima Rehabilitation Centre, Hiroshima University
15 Hospital, Kyoto University Siemens Trio scanner, and Kyoto University Siemens Prisma
16 scanner. It also included the Taiwanese cohort (Taipei Medical University) and the Centre of
17 Biomedical Research Excellence open dataset
18 (http://fcon_1000.projects.nitrc.org/indi/retro/cobre.html), along with the Johns Hopkins
19 University cohort (United States), which included HCs and patients with early-stage SSD. The
20 total number of participants was 708 (405 HCs, 198 patients with SSD, and 105 patients with
21 MDD).

22 Clinical scale scores: Positive and Negative Syndrome Scale (PANSS)¹⁹ and Peters et
23 al. Delusions Inventory (PDI) 21-item version²⁰ and information about the dosage of

1 antipsychotics were available from a subset of participants in both datasets (**Supplementary**
2 **Table 2**).

3 This study was conducted in accordance with the recommendations of the review
4 boards of institutions affiliated with the principal investigators—namely, Hiroshima
5 University, Kyoto University, SWA, and UTO. Most of the material data in this study can be
6 downloaded from the DecNef Project Brain Data Repository²¹
7 (<https://bicr-resource.atr.jp/srpbsopen/>).

8 **Data acquisition**

9 All data in the discovery dataset were collected using a unified protocol developed by a
10 national project (Strategic Research Program for Brain Science [SRPBS] & Brain/Mind
11 Beyond) in Japan²¹. The MRI data comprised a T1-weighted structural image, rs-fMRI
12 acquired using an echo-planar imaging technique, and field map images. The duration of
13 rs-fMRI was 10 min. The participants were instructed to relax, stay awake, fixate on the central
14 crosshair mark, and not concentrate on specific things. The MRI data for the validation dataset
15 included a structural image and rs-fMRI similar to the discovery dataset; however, some of the
16 data lacked fieldmap images. Scanning parameters for the validation dataset varied by site. The
17 duration of rs-fMRI was approximately 4–6 min. Detailed imaging parameters for both
18 datasets are provided in **Supplementary Table 3**.

19 **Preprocessing**

20 The data were preprocessed according to a previous report²². fMRIPrep version 20.1.11 was
21 used for data preprocessing²³. First, the first four volumes of the rs-fMRI scan were discarded
22 for T1 equilibration. The preprocessing steps were as follows: slice-timing correction,
23 realignment, coregistration, susceptibility-induced distortion correction using field maps,

1 segmentation of a T1-weighted structural image, normalisation to Montreal Neurological
2 Institute space, and spatial smoothing with an isotropic Gaussian kernel of 6 mm full-width at
3 half-maximum. For the participants without field maps in the validation dataset, we applied
4 ‘fieldmap-less’ distortion correction implemented in fMRIPrep. Further details of the pipeline
5 are available at <http://fmriprep.readthedocs.io/en/latest/workflows.html>.

6 **Signal extraction**

7 We used two approaches for fMRI signal extraction: (1) a surface-based approach following
8 the Human Connectome Project pipelines (using the ciftify toolbox version 2.3.2²⁴, we
9 converted volume-based MRI data into data based on ‘greyordinate’ [cortical grey matter
10 surface vertices and subcortical grey matter voxels]) and (2) an approach based on the regions
11 of interest (ROIs). For reliable surface-based brain parcellation, we adopted the ROIs from
12 Glasser et al.²⁵ (379 parcels in total, comprising 360 cortical parcels as surface ROIs and 19
13 subcortical parcels as volume ROIs). Using these approaches, we extracted BOLD signal time
14 courses from 379 ROIs. To compare these ROIs with conventional annotations of brain areas
15 and intrinsic brain networks, we referred to the Anatomical Automatic Labelling (AAL) and Ji
16 et al.²⁶, respectively.

17 **Noise removal**

18 We used component-based noise correction (CompCor)²⁷ to detect physiological noise.
19 Anatomical CompCor was applied to the subcortical white matter and cerebrospinal fluid
20 regions, and the top five principal components were estimated as physiological noise, except
21 for one participant who had only four components. Accordingly, we regressed out these
22 components together with six head-motion parameters and averaged the signals over the entire
23 brain.

1 **Temporal filtering**

2 We used temporal bandpass filtering ranging from 0.01 to 0.08 Hz²⁸ to the time series of
3 rs-fMRI to extract the low-frequency brain activity characterising resting state.

4 **Data scrubbing**

5 We removed volumes with considerable head motion based on framewise displacement (FD)²⁹.
6 FD was calculated as the sum of the absolute displacements in translation and rotation between
7 two consecutive volumes. We removed volumes with $FD > 0.5$ mm, as proposed in a previous
8 study²⁹. In addition, participants whose scrubbed volume ratio exceeded the mean +3 S.D. were
9 excluded.

10 **Calculation of the FC matrices**

11 We defined FC as the temporal correlation of rs-fMRI BOLD signals between two ROIs. We
12 calculated Pearson's correlation coefficient of the preprocessed BOLD time series between
13 each pair of ROIs out of Glasser's 379 ROIs. Fisher's Z-transformed values of the correlation
14 coefficients constituted an FC matrix for each participant, where the total number of FC was
15 $\binom{379}{2} = 71\,631$.

16 **Harmonisation of the site differences**

17 We harmonised the site effects in the discovery dataset prospectively²¹ using a unified imaging
18 protocol under the SRPBS & Brain/Mind Beyond project and retrospectively using the
19 travelling subject method⁹. Regarding the travelling subject method, site effects were
20 separately estimated as measurement bias and sampling bias from the rs-fMRI data of these
21 travelling subjects, each of whom underwent scans at multiple sites⁹. We subtracted the

1 estimated measurement bias to obtain harmonised connectivity data (see **Supplementary Text**
2 **1**). For the validation dataset, we applied the ComBat harmonisation method^{30–32}. In the
3 execution of ComBat harmonisation, we inputted the diagnosis, PANSS total score, PDI total
4 score, age, sex, handedness, and duration of illness (DOI) (for patients with SSD) as auxiliary
5 variables to correct measurement bias.

6 **Diagnostic classifiers for SSD**

7 Next, we constructed classifiers to differentiate patients with SSD from HCs using machine
8 learning based on 71 631 FC values as features. In subsequent sections, we used only the data
9 of HCs and patients with SSD, except for generalising the models to other disorders. Initially,
10 we used a customised sparse learning algorithm, specifically least absolute shrinkage and
11 selection operator (LASSO), similar to our previous work on MDD²⁶. The sparse method in
12 LASSO can prevent overfitting and simultaneously select important features (for the detailed
13 methodology, refer to **Supplementary Text 2**). Although we used LASSO to identify
14 important FCs for SSD classification, we applied a voting method³³ to enhance the
15 classification performance of the LASSO classifiers.

16 **Building LASSO classifiers**

17 As illustrated in **Supplementary Figure 1a**, we implemented a nested 10-fold cross
18 validation (CV) scheme. In the outer loop, we divided the discovery dataset into 10 folds. After
19 leaving one fold as the test set, the remaining nine folds were used as the training set. To
20 minimise the bias arising from the imbalance between the number of patients with SSD and
21 HCs, we conducted subsampling with undersampling simultaneously. We randomly sampled
22 the same number ($N=102$) of HCs and SSDs from the training set, creating a subsample.
23 During subsampling and undersampling, we matched the mean ages of HCs and SSDs. We fit

1 the logistic regression model to the subsample while tuning a hyperparameter with an
2 inner-loop 10-fold CV (for the detailed methodology, see **Supplementary Text 2**). By
3 repeating random subsampling and fitting the model 10 times, we obtained 10 classifiers. We
4 then predicted SSD probability for each participant in the test set. By applying the 10 classifiers
5 built from a training set to a test set in each CV, we obtained the probability values for the
6 participant as the classifier outputs. When the mean probability value was >0.5 , we considered
7 the participant's class as SSD; otherwise, as HC. Finally, by repeating the above procedure 10
8 times in the outer loop, 100 classifiers were obtained.

9 We evaluated the performance of the classifiers using the following indices: an area
10 under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and
11 Matthews' correlation coefficient (MCC) (see **Supplementary Text 3** for details).

12 **Independent validation of LASSO classifiers**

13 To assess the generalisability of the obtained classifiers, we tested them on the validation
14 dataset. We applied the 100 classifiers to each participant in the validation dataset to compute
15 diagnostic probability values for each participant (**Supplementary Figure 1b**). We classified a
16 participant as having SSD if the average probability value was >0.5 .

17 We also performed a statistical analysis of the classification performance for
18 independent validation using a permutation test. We created 100 quasi-classifiers using the
19 same procedure as for building genuine classifiers, with the participants' classes permuted in
20 the discovery dataset. We predicted the diagnosis in the same manner as mentioned above
21 using the quasi-classifiers on the validation dataset for each permutation. By repeating random
22 permutations 500 times and obtaining null distributions of the AUC and MCC, we evaluated
23 the statistical significance of the true classifiers.

1 **Identifying important FCs for predicting diagnosis**

2 We investigated which FCs were utilised to predict the diagnosis in each classifier by
3 identifying the nonzero coefficients in LASSO. We counted the number of classifiers (out of
4 100) that selected each FC as an explanatory variable. We performed a permutation test to
5 identify the most informative FCs from 71 631 FCs. Each time we randomly permuted the
6 class labels of participants in the discovery dataset, we built 100 quasi-classifiers using 10-fold
7 CV with 10-time subsampling, following the methodology described in the previous section
8 (see '**Building LASSO classifiers**' section). We determined the maximum counts for which
9 each FC was selected as a predictive explanatory variable using 100 quasi-classifiers for each
10 permutation. This procedure was repeated 100 times, resulting in a null distribution of 100
11 values for the maximum selection count. An FC was considered significantly informative
12 ('important FC') when the selection count in the genuine 100 classifiers exceeded the threshold
13 that corresponded to $P < 0.05$ in the null distribution.

14 **Voting classifiers**

15 In addition to logistic regression with LASSO, we attempted to enhance the performance by
16 introducing a voting method³³. We incorporated support vector machine³⁴, random forest³⁵,
17 light gradient boosting machine³⁶, and multi-layer perceptron³⁷ as representative algorithms.
18 For each algorithm, we conducted CV, subsampling with undersampling, and training on the
19 discovery dataset following the same procedure used to build the LASSO classifiers (for
20 detailed methodology, see **Supplementary Text 4**).

21 To statistically compare the classification capability of the voting classifiers with that
22 of the LASSO classifiers, we used the R programmes Compbdt and pROC. Using Compbdt³⁸,
23 we compared the two classifiers based on their sensitivity and specificity using the McNemar

1 test. We used pROC to conduct DeLong's test on the AUC. The significance level for all tests
2 was set at $P < 0.05$.

3 **Application of the classifiers to other psychiatric disorders**

4 We assessed the specificity of the classifiers for SSD by applying them to data from
5 participants with other mental disorders, MDD, ASD, and BP. Regarding the LASSO
6 classifiers, we applied 100 classifiers to all the patients with these disorders from the discovery
7 and validation datasets. If the output probability was >0.5 , the participants were assumed to
8 have SSD-like characteristics. Regarding the voting classifiers, we applied 500 classifiers to
9 the same patients, and the participants were assumed to be SSD-like if over half (>250) of the
10 classifiers predicted as such. The discovery dataset included patients with MDD, ASD, and BP,
11 whereas the validation dataset only included patients with MDD. The outputs of the classifiers
12 for HC and SSD were used for the comparison with MDD, ASD, and BP. Specifically, the
13 output for test data in the 10-fold CV was used in the discovery dataset, and the output of 100
14 classifiers was used in the validation dataset.

15 To evaluate if the classifying results of patients with any of the other disorders (MDD,
16 ASD, BP) had similarity to HC, SSD, or neither, we conducted a two-sided binomial test
17 (significance level, $P < 0.05$). We also assessed whether each probability density curve was
18 differently distributed using the two-sample Kolmogorov–Smirnov test. We conducted this test
19 for every combination of HC, SSD, MDD, ASD, and BP; thus, 10 combinations were obtained
20 in total. The level of significance was $P < 0.05/10 = 0.005$ (Bonferroni-corrected).

21 **Prediction of clinical scores using important FCs**

22 Another objective of this study was to determine the extendibility of the trait marker to the state
23 or disease stage. In the first part of this investigation, we attempted to predict the scores of two

1 clinical scales with important FCs *in the aggregate* so we could aid clinical assessment and
2 estimate the extent to which our biomarker could function as a trait and/or state marker using
3 the PDI and PANSS total scores. These scales have been widely used to assess delusional
4 thinking and psychotic syndrome³⁹. PDI may reflect trait²⁰ and state⁴⁰, whereas the PANSS
5 may reflect the overall symptom severity of psychosis at that time point (state)⁴¹.

6 We predicted the scores on the clinical scales (PDI and PANSS total scores) using
7 important FCs as explanatory variables. We applied a nested 10-fold CV scheme to the
8 discovery dataset (only SSD participants with available target scale scores) to build prediction
9 models (**Supplementary Figure 2a**). In the outer loop, we divided the discovery dataset into
10 10 folds. After leaving one fold as the test set, we used the remaining nine folds as the training
11 set. We fitted the linear regression model to the training set (the *LinearRegression* module in
12 scikit-learn version 0.24.1). In the inner loop, we searched for the most suitable number of
13 important FCs to be used as features to avoid overfitting (for the detailed methodology, see
14 **Supplementary Text 5 and Supplementary Figure 2b**). We predicted the score for each
15 participant in the test set using a linear regression model with the best number of features for
16 the fold. Using 10-fold CV, we obtained 10 models with different numbers of features. For the
17 validation dataset, we averaged the outputs from the 10 models to create the final predicted
18 score (**Supplementary Figure 2c**). At any step of this analysis, the predicted value was
19 adjusted within the range of the scale score (if the prediction was lower than the lowest possible
20 value, it was adjusted to the lowest possible value, and vice versa).

21 We conducted a permutation test to assess the evaluation metrics statistically.
22 Specifically, we permuted clinical labels (diagnosis and symptom scores) against FC values,
23 created quasi-models following the same procedure as the genuine models, and repeated these
24 steps 500 times to obtain a null distribution of the evaluation metrics. Differences were
25 considered statistically significant if each evaluation metric for the genuine models was better

1 than the cut-off value of $P=0.05$ of the null distribution.

2 **Separately identifying FCs associated with the state**

3 Next, we explored the roles of individual FCs. To identify the FCs associated with state (i.e.
4 symptom scale scores), we performed multiple regression analyses on each of the important
5 FCs. We selected PANSS as the state index because it dynamically changes with treatment and
6 has been used as a representative scale for the state of schizophrenia. All HC participants and
7 patients with SSD having data on PANSS scores across the discovery and validation datasets
8 were included in the analysis. We examined two models of the PANSS: the original three-factor
9 model¹⁹ composed of positive, negative, and general pathological factors and the five-factor
10 model⁴¹ composed of positive, negative, disorganised, excited, and depressed factors. Because
11 the general pathological factor was not categorised as a specific symptom dimension, we used
12 only positive and negative factors as explanatory variables for the three-factor model.

13 Owing to the exploratory nature of this analysis, we converted the PANSS scores into
14 explanatory variables in two ways: by min–max normalisation and binary dummy variables.
15 The formula to fit was the same for both methods:

$$16 \quad FC = \beta_0 + \beta_1 x_t + \sum_{j=1}^{n_{factor}} (\beta_{j+1} x_{s_j}) + e \quad (\text{Eq. 1})$$

17 where x_t represents the trait or diagnosis (HC: 0, SSD: 1), x_{s_j} represents the existence of
18 symptoms for the j th factor of the PANSS, and e represents a random error.

19 *Conversion 1. Min–max normalisation of the scores*

20 The value x_{s_j} was determined using the following formula:

$$21 \quad x_{s_j} = \frac{m_j - \min(m_j)}{\max(m_j) - \min(m_j)} \quad (\text{Eq. 2})$$

22 where m_j represents the participant's average score in the j th factor of the PANSS and
23 $\min(m_j)$ (or $\max(m_j)$) represents the minimum (or maximum) average score of the j th

1 PANSS factor across all patients with SSD with available PANSS subscore data.

2 *Conversion 2. Binarising the scores*

3
$$x_{s_j} = \begin{cases} 0 & \text{if } m_j \leq 2 \\ 1 & \text{if } m_j > 2 \end{cases} \quad (\text{Eq. 3})$$

4 The value x_{s_j} was determined as in Eq.3 as three points or more is considered pathological in

5 PANSS rating.

6 All s_j for HC participants were assumed to be zero. In the regression analysis for

7 each FC, the FC was regarded as a potential state marker when any of the coefficient estimates

8 for PANSS factor ($\beta_{(j+1)}, j = 1, 2, \dots, n_{\text{factor}}$) was nonzero at a significance level $P < 0.05$ with a

9 one-sample t -test. We reported FCs as being significant only when the state's coefficient

10 concerned ($\beta_{(j+1)}$) was of the same sign as w of the FC in terms of consistency with the

11 underlying LASSO classifiers.

12 **Identifying FCs associated with the disease stage**

13 Finally, we constructed another multiple regression model to identify FCs associated with the

14 disease stage of SSD, which could be referred to as 'staging' markers. Following a pre-existing

15 definition^{42,43}, we divided the SSD group into an early-stage psychosis subgroup (DOI of <5

16 years) and a chronic-stage subgroup (DOI of ≥ 5 years). We formulated a regression model

17 similar to that described in the previous section:

18
$$FC = \beta_0 + \beta_1 x_t + \beta_2 x_e + \beta_3 x_c + \beta_4 x_a + e \quad (\text{Eq. 4})$$

19
$$\text{such that } x_e = \begin{cases} 1 & \text{if } DOI < 5 \text{ yrs.} \\ 0 & \text{if } DOI \geq 5 \text{ yrs.} \end{cases}, \quad x_c = \begin{cases} 0 & \text{if } DOI < 5 \text{ yrs.} \\ 1 & \text{if } DOI \geq 5 \text{ yrs.} \end{cases} \quad (\text{Eq. 5})$$

20 where x_e represents the early stage of SSD, x_c represents the chronic stage, and x_t and e

21 were defined in the same way as in Eq. 1. The value x_a , the age of the participant, was

22 introduced as a covariate because the DOI was supposed to correlate with age. All HC

23 participants and patients with SSD with DOI data across the discovery and validation datasets

1 were included in the analysis. Using this model, we categorised important FCs into six groups
2 based on which trait, early/chronic stage, was significantly associated: (1) trait only, (2) early
3 stage only, (3) chronic stage only, (4) trait and early stage, (5) trait and chronic stage, and (6) all
4 three. In terms of consistency with our classifiers and within the coefficients, every coefficient
5 estimate concerned must be of the same sign as $w_.$; statistical significance was determined at
6 the level $P < 0.05$, with a one-sample t -test for each coefficient estimate. Considering the
7 relative instability of the model fit due to singularity, we adopted the bootstrap method (1,000
8 iterations) to count the number of times a certain FC was sorted into each category.

1 RESULTS

2 Datasets

3 Fifty-one participants whose scrubbed rs-fMRI volumes exceeded +3 standard deviations
4 (SDs) were excluded from all datasets. Therefore, 1,015 participants in the discovery dataset
5 and 683 participants in the validation dataset were included for further analyses. Through the
6 scrubbing process, $9.2 \pm 17.9\%$ (mean \pm SD) of whole volumes per rs-fMRI scan were removed
7 across all datasets.

8 Performance of the LASSO classifiers

9 Within the discovery dataset, classification accuracy was 79.6%, with an AUC of 0.876.
10 Sensitivity, specificity, and MCC were 81.5%, 79.2%, and 0.484, respectively. The density
11 curve of HCs and patients with SSD is shown in **Figure 2a**, where a patient with a predicted
12 probability of >0.5 was classified as a patient and vice versa. The curves for each site are
13 shown in **Figure 2b**.

14 Within the validation dataset, the classifiers distinguished patients with SSD from
15 HCs with 77.3% accuracy and an AUC of 0.824, similar to the results from the discovery
16 dataset (**Figure 2c, d**). Sensitivity, specificity, and MCC were 69.2%, 81.1%, and 0.490,
17 respectively. A permutation test revealed that the AUC and MCC were significantly high
18 ($P < 0.001$). At JHU, the classifiers correctly distinguished HCs in most cases (specificity,
19 83.6%), but not patients with SSD (sensitivity, 40.6%). The probability density curve of SSD
20 was closer to that of HC ($P = 0.37$, two-sided binomial test), although the distribution of the two
21 curves was significantly different ($P = 0.013$, two-sample Kolmogorov–Smirnov test),
22 suggesting that patients with early-stage SSD at JHU fell between chronic-stage SSD and HC.

1 **Important FCs for predicting diagnosis**

2 At $P < 0.05$ in the permutation test, the FCs selected by ≥ 17 classifiers were deemed important.

3 Ultimately, we identified 47 important FCs, as shown in **Figure 3a, b** and detailed in

4 **Supplementary Table 4.**

5 Furthermore, we investigated the detailed patterns of FC value differences between
6 the HC and SSD groups and their reproducibility across the two datasets by plotting the mean
7 values for 47 FCs, facilitating a comparison between the datasets (**Figure 3c**). The relationship
8 between the mean FC values of the HC and SSD groups was maintained in the validation
9 dataset for 44 of 47 FCs.

10 **Voting classifiers**

11 **Supplementary Figure 3a, b** displays the probability density curve of the voting classifier's
12 output through 10-fold CV in the discovery dataset.

13 Independent validation for all sites in the validation dataset is presented in
14 **Supplementary Figure 3c, d**. We conducted statistical tests to compare the performance of the
15 voting classifiers with that of the LASSO classifiers. Sensitivity was significantly higher for
16 the voting classifiers than for the LASSO classifiers ($P < 0.001$, McNemar test, two-sided).
17 However, specificity showed no significant difference between groups ($P = 0.192$, McNemar
18 test, two-sided). The AUC of the voting classifiers was 0.841, which was not significantly
19 different from that of LASSO classifiers ($P = 0.11$, DeLong's test).

20 **Supplementary analyses on classifiers' characteristics**

21 LASSO and voting classifiers were built on subsamples in which the mean ages of the
22 HC and SSD groups were matched to mitigate the confounding effect of age. Furthermore, we

1 evaluated whether the classifiers' performance was influenced by confounding factors (see
2 **Supplementary Text 6** and **Supplementary Table 5**). Consequently, the performance of
3 voting classifiers could be partly influenced by age but not by other potential confounding
4 factors. In contrast, the LASSO classifiers were unaffected by any potential confounding
5 variables.

6 We also investigated how the classification performance varied based on disease
7 severity in the validation dataset. Following a previous report⁴⁴, we identified subgroups with
8 different severities based on PANSS total scores: mild ($PANSS \leq 58$, $N=55$), moderate
9 ($58 < PANSS \leq 75$, $N=36$), marked ($75 < PANSS \leq 95$, $N=20$), severe ($95 < PANSS \leq 116$, $N=1$), and
10 most severe ($116 < PANSS$, $N=0$). Except for the severe and most severe subgroups, each of
11 which contained only one or no participants, the sensitivity by subgroup was highest in the
12 marked subgroup, followed by the mild and moderate subgroups (**Supplementary Table 6**).
13 This order of performance was consistent for the LASSO and voting classifiers, but the
14 disparity among the subgroups decreased for the voting classifiers compared with the LASSO,
15 suggesting that voting classifiers can predict classes with less imbalance across different
16 disease severity levels.

17 **Classifier specificity for SSD**

18 The LASSO classifiers revealed that the patients with ASD and BP did not exhibit high- or
19 low-SSD-like characteristics. However, patients with MDD were less SSD-like ($P=2.24 \times 10^{-7}$),
20 resembling the HCs (**Supplementary Figure 4, Supplementary Table 7**). Voting classifiers
21 showed a similar pattern. These results suggest that both classifiers exhibited high specificity
22 for SSD.

23 Moreover, we investigated whether each probability density curve was distributed
24 differently. The LASSO and voting classifiers revealed that the curve of each non-SSD

1 disorder had a significantly different distribution from those of HC and SSD in the discovery
2 and validation datasets (**Supplementary Table 8**). Furthermore, the curves for any two
3 non-SSD disorders showed no significant differences.

4 **Prediction of clinical scale scores using important FCs**

5 Regarding PDI total scores, the results of 10-fold CV in the discovery dataset were acceptable
6 ($r=0.231$, 95% confidence interval [CI]=[0.00101–0.438], $P=0.0492$, two-sided, mean
7 absolute error [MAE]=40.0). Weak correlations between the actual and predicted scores were
8 observed in the validation dataset ($r=0.331$, 95% CI=[0.0609–0.556], $R^2=0.110$, $P=0.0177$,
9 two-sided, MAE=55.5) (**Figure 4a**). A permutation test was conducted to objectively assess
10 whether the evaluation metrics were satisfactory. The correlation coefficients were
11 significantly high ($P_{\text{perm}}=0.01$) and MAE significantly low ($P_{\text{perm}}=0.018$).

12 Concerning PANSS total scores, the 10-fold CV in the discovery dataset resulted in no
13 correlation between actual and predicted scores ($r=-0.0065$, 95% CI=[-0.199–0.186],
14 $P=0.948$, two-sided, MAE=17.5). The model did not predict scores in the validation dataset
15 either ($r=0.128$, 95% CI=[-0.0588–0.306], $R^2=0.016$, $P=0.178$, two-sided, MAE=16.8)
16 (**Figure 4b**).

17 In summary, we predicted the PDI total score more efficiently than the PANSS total
18 score, suggesting that, collectively, the important FCs may function as trait and state markers.

19 **Individual FCs associated with PANSS factors**

20 In total, 17 FCs were significantly associated with the PANSS factors. Using the three-factor
21 model of PANSS, we identified significant associations in FCs #45 (R.TPOJ1 and R.Thalamus,
22 with the PANSS positive factor) and #8 (L.1 and R.3b, with the PANSS negative factor),
23 regardless of the score conversion method (**Table 2, Supplementary Table 9**). With the

1 five-factor model of PANSS, we found that the significantly associated FCs, regardless of
2 conversion method, were FCs #18 (L.FOP1 and R.Putamen), #41 (R.6a and R.PoI1), #43
3 (R.FOP4 and R.Putamen) with the excited factor, and FC #27 (R.RSC and R.SFL) with the
4 depressed factor.

5 When the coefficient estimate was significant only for a state (not for the trait), such
6 FCs were assumed to be ‘pure’ state markers. We found nine FCs (**Table 2**). Among these FCs,
7 FC #27 (R.RSC and R.SFL) was the only one consistently identified as a ‘pure’ state marker,
8 regardless of conversion method.

9 **Individual FCs associated with disease stage**

10 **Figure 4c** presents the results of categorising important FCs into subgroups associated with
11 trait (diagnosis), the early stage, or the chronic stage of SSD using the bootstrapping method
12 (1,000 iterations). We assumed that an FC belonged to a certain category with consistent
13 regression results for over half (>500) of the iterations. Subsequently, the important FCs were
14 categorised most frequently as ‘trait and chronic stage’ (61.7%), followed by ‘trait and early
15 stage’ (6.4%), ‘trait only’ (2.1%), and ‘trait, early, and chronic stage’ (2.1%). No FCs were
16 categorised as ‘early stage only’ or ‘chronic stage only,’ indicating that we did not identify any
17 pure staging markers.

1 DISCUSSION

2 We developed rs-FC classifiers for SSD based on harmonised multicentre data and validated it
3 using large-sample independent data. This study also aimed to maximise the potential of the
4 rs-FC biomarker to function as a state marker and a staging marker.

5 The accuracy of the identified diagnostic marker was approximately 80% for the
6 discovery dataset. It demonstrated comparable performance in an external validation with
7 seven international cohorts; this presents a sharp contrast to previous studies¹⁰. This
8 achievement was possible through bi-directional (prospective and retrospective) harmonisation
9 and with optimised machine learning method. Against the concerns on session variability of
10 rsfMRI, we reduced the variability and improved generalisability to independent validation
11 cohorts through spatial averaging of 100 classifiers, each analysing tens of FCs. Furthermore, a
12 previous study⁴⁵ revealed that test–retest reliability was acceptable with the same methodology
13 as demonstrated in this study.

14 The LASSO and voting classifiers exhibited distinct performance characteristics.
15 Voting classifiers demonstrated superiority in sensitivity and a more balanced profile over
16 LASSO classifiers, with the accuracy, sensitivity, and specificity falling within a narrow range
17 (LASSO: 69.2–81.1%, voting: 74.7–78.8%) in independent validation.

18 We identified important FCs that significantly contributed more frequently to SSD
19 classification in LASSO classifiers. Based on AAL, the putamen, insula, thalamus, and
20 cingulum were among the top ROIs most frequently found in the important FCs
21 (**Supplementary Table 10**). In schizophrenia research, these are consistently implicated in
22 grey matter volume reduction⁴⁶ or FC abnormality^{47,48}. Moreover, these ROIs were associated
23 with the cortico-striatal-thalamic-cortical loop and salience network, both recognised for their
24 pivotal roles in the psychopathology of SSD⁴⁹. In the context of FC, hypoconnectivity between

1 the putamen and anterior cingulate cortex (FC #13, #30, #37, #38) in the SSD group aligns with
2 a previous report⁵⁰, where greater ACC–putamen connectivity predicted better treatment
3 response. Conversely, in the SSD group, the thalamus exhibited increased connectivity with
4 various cortical ROIs (FC #11, #12, #24, #25, #35, #36, and #45), corresponding with a report⁵¹
5 on thalamocortical connectivity in schizophrenia, implying disrupted information filtering in
6 SSD, consistent with the literature⁵². Therefore, these important FCs aptly reflected the neural
7 correlates of schizophrenia and were considered trait markers of SSD.

8 We observed that our classifiers exhibited high specificity for SSD, whereas other
9 diagnoses (MDD, ASD, and BP) did not show specificity for HC or SSD. These psychiatric
10 disorders share several characteristics with SSD in the alteration pattern of brain function^{53–55}.
11 Moreover, these disorders have similar phenotypes (e.g. cortical thickness) and genotypes⁵⁶.
12 Thus, our biomarkers may, to some extent, reflect neural changes common to psychiatric
13 disorders⁵⁷.

14 The second objective of this study was to dissect the biomarker into a ‘trait marker’
15 and other components. Using aggregated important FCs, we achieved an acceptable level of
16 prediction for the PDI but not for the PANSS, indicating that aggregated FCs were more
17 strongly associated with traits. Few groups have reported successful prediction of symptoms
18 using FC^{58,59}; however, these studies lacked external validation. In this study, the predicted PDI
19 total score was significantly correlated to the actual score in the discovery and validation
20 datasets.

21 Using multiple regression analysis, we identified state markers individually. Using the
22 three-factor model of the PANSS, we observed a significant association between positive
23 scores and FC #45 and negative scores and FC #8, irrespective of the score conversion method.
24 Evidence suggests that FC #45 significantly correlates with positive symptoms⁶⁰. FC #8 also
25 showed a significant association with the negative and disorganised factors of the five-factor

1 model, which could be linked to the finding that interhemispheric connectivity of the precentral
2 and postcentral gyri were negatively correlated with the PANSS total score⁶¹.

3 We discovered interesting overlaps of ROIs in the potential state marker FCs.
4 Concerning negative and depressed factors, sensorimotor areas were noticeable. Specific
5 functional alterations in these ROIs related to neurological soft signs (NSSs) have been
6 reported⁶². Moreover, NSSs correlate with PANSS negative scores and depression scale
7 scores⁶³. The excited factor seems to involve the putamen, insula, Rolandic operculum, and
8 middle cingulum, regions likely to be associated with aggression⁶⁴. The Rolandic operculum
9 and middle cingulum are related to aggression via disruption of the cognitive control
10 network⁶⁵.

11 Neuromodulation can be a novel psychiatric treatment, and one of the promising
12 techniques is neurofeedback (Nef). There is accumulating evidence on the therapeutic effect
13 of Nef targeting FCs^{66,67}. Our findings on state markers will benefit future FC-Nef in target
14 selection.

15 Although we did not discover any pure staging markers, our results provide a
16 compelling argument for ‘trait and early stage’ markers exemplified by FCs #16, #20, and #23.
17 FCs #20 and #23 represented connections between regions around the superior temporal sulcus
18 (STS) or gyrus (STG). A task-based fMRI study on working memory showed attenuated
19 activity in the STG in patients with early-stage psychosis compared with HCs⁶⁸. Moreover, the
20 cortical thickness of the insula (an ROI in FC #16) and the STS region are reduced in
21 early-stage psychosis⁶⁹. These suggest that our biomarker partly include staging marker.
22 Additionally, the fact that the probability curve for patients with early-stage psychosis at JHU
23 lies in the middle between the HC and SSD groups may also support this argument.

24 This study has some limitations. First, the participants with SSD in our study were
25 mostly medicated; hence, the applicability of our results to drug-naive patients cannot be

1 guaranteed. Second, we only confirmed that our classifiers distinguished patients with SSD
2 from healthy individuals, not from individuals with other psychiatric disorders exhibiting
3 psychotic symptoms. Further studies are required to test the classifiers for these disorders to
4 maximise the clinical applicability.

5 In conclusion, we developed robust and clinically usable classifiers for SSD using a
6 combination of cutting-edge strategies. While constructing the classifiers, we identified FCs
7 that may play key roles in SSD pathophysiology. We also demonstrated that these ‘important
8 FCs’ had multiple functions as SSD trait, state, or staging markers. Our findings shed new light
9 on the early diagnosis of SSD and the selection of targets for neuromodulation.

1 **Acknowledgements**

2 We thank Editage (www.editage.com) for the English language editing.

3

4 **Funding**

5 This study was supported by KAKENHI JP (23H04979) from the Ministry of Education,

6 Culture, Sports, Science and Technology of Japan, AMED (Grant Numbers: JP23dm0307008,

7 JP19dm0207069, JP18dm0307001, JP18dm0307004, JP18dm0307008, and

8 JP18dm0307009), and CREST (JPMJCR22P3) from the Japan Science and Technology

9 Agency. OY received support from the Japan Agency for Medical Research and Development

10 (AMED) (Grant Number JP23dm0307009). TM received support from a Grant-in-Aid for

11 Transformative Research Areas (A) (Japan Society for The Promotion of Science,

12 JP21H05173), Grant-in-Aid for Scientific Research (B) (Japan Society for The Promotion of

13 Science, 21H02849), and Strategic International Brain Science Research Promotion Program

14 (Brain/MINDS Beyond) (21dm0307102h0003) of the AMED. JM received support from the

15 AMED (Grant Number JP21uk1024002) and KAKENHI (JP20H05064).

16

17 **Author contributions**

18 T.K., A.Y., M.K., and H.T. designed the study. T.K., Y.Y., Y.K., N.O, K.K., M-C.H., A.S., T.M.,

19 J.M., and H.T. recruited participants for the study and collected their clinical and imaging data.

20 T.K. and A.Y. performed the data analysis. T.K., A.Y., and J.M. wrote the original draft of the

21 manuscript. T.K., A.Y., Y.Y., Y.K., N.O, K.K., M-C.H., A.S., J.Y., O.Y., T.M., J.M., M.K., and

22 H.T. reviewed and revised the manuscript.

23

24 **Conflict of interest**

25 MK is an inventor of patents owned by the Advanced Telecommunications Research Institute

- 1 International related to the present work (PCT/JP2014/061544 [WO2014178323] and
- 2 JP2015-228970/6195329). AY and MK are inventors of a patent application submitted by the
- 3 Advanced Telecommunications Research Institute International related to the present work
- 4 (JP2018-192842).

1 REFERENCES

- 2 1. Abi-Dargham, A. & Horga, G. The search for imaging biomarkers in psychiatric
3 disorders. *Nat. Med.* **22**, 1248–1255 (2016).
- 4 2. Kraguljac, N. V. *et al.* Neuroimaging biomarkers in schizophrenia. *Am. J. Psychiatry*
5 *appi.ajp.2020.2* (2021) doi:10.1176/appi.ajp.2020.20030340.
- 6 3. Cai, X. *et al.* Generalizability of machine learning for classification of schizophrenia
7 based on resting-state functional MRI data. *Hum. Brain Mapp.* **41**, 172–184 (2020).
- 8 4. Parkes, L., Satterthwaite, T. D. & Bassett, D. S. Towards precise resting-state fMRI
9 biomarkers in psychiatry: synthesizing developments in transdiagnostic research, dimensional
10 models of psychopathology, and normative neurodevelopment. *Curr. Opin. Neurobiol.* **65**,
11 120–128 (2020).
- 12 5. Steyerberg, E. W. & Harrell, F. E. Prediction models need appropriate internal,
13 internal–external, and external validation. *J. Clin. Epidemiol.* **69**, 245–247 (2016).
- 14 6. Winterburn, J. L. *et al.* Can we accurately classify schizophrenia patients from healthy
15 controls using magnetic resonance imaging and machine learning? A multi-method and
16 multi-dataset study. *Schizophr. Res.* **214**, 3–10 (2019).
- 17 7. Li, C. *et al.* *Classification of Schizophrenia Spectrum Disorder Using Machine*
18 *Learning and Functional Connectivity: Reconsidering the Clinical Application.*
19 <http://medrxiv.org/lookup/doi/10.1101/2020.05.30.20118026> (2020)
20 doi:10.1101/2020.05.30.20118026.
- 21 8. Schnack, H. G. & Kahn, R. S. Detecting neuroimaging biomarkers for psychiatric
22 disorders: Sample size matters. *Front. Psychiatry* **7**, (2016).
- 23 9. Yamashita, A. *et al.* Harmonization of resting-state functional MRI data across
24 multiple imaging sites via the separation of site differences into sampling bias and

- 1 measurement bias. *PLOS Biol.* **17**, e3000042 (2019).
- 2 10. Porter, A. *et al.* A meta-analysis and systematic review of single vs. multimodal
3 neuroimaging techniques in the classification of psychosis. *Mol. Psychiatry* **28**, 3278–3292
4 (2023).
- 5 11. Noble, S., Scheinost, D. & Constable, R. T. A decade of test-retest reliability of
6 functional connectivity: A systematic review and meta-analysis. *NeuroImage* **203**, 116157
7 (2019).
- 8 12. Lema, Y. Y., Gamo, N. J., Yang, K. & Ishizuka, K. Trait and state biomarkers for
9 psychiatric disorders: Importance of infrastructure to bridge the gap between basic and clinical
10 research and industry: Trait and state biomarkers in psychiatry. *Psychiatry Clin. Neurosci.* **72**,
11 482–489 (2018).
- 12 13. Spellman, T. & Liston, C. Toward circuit mechanisms of pathophysiology in
13 depression. *Am. J. Psychiatry* **177**, 381–390 (2020).
- 14 14. McGorry, P. *et al.* Biomarkers and clinical staging in psychiatry. *World Psychiatry* **13**,
15 211–223 (2014).
- 16 15. Martínez-Cao, C. *et al.* Is it possible to stage schizophrenia? A systematic review.
17 *Transl. Psychiatry* **12**, 197 (2022).
- 18 16. Yahata, N., Morimoto, J. & Hashimoto, R. A small number of abnormal brain
19 connections predicts adult autism spectrum disorder. *Nat. Commun.* **7**, (2016).
- 20 17. Yoshihara, Y. *et al.* Overlapping but asymmetrical relationships between
21 schizophrenia and autism revealed by brain connectivity. *Schizophr. Bull.* **46**, 1210–1218
22 (2020).
- 23 18. Ichikawa, N. *et al.* Primary functional brain connections associated with melancholic
24 major depressive disorder and modulation by antidepressants. *Sci. Rep.* **10**, 3542 (2020).
- 25 19. Kay, S. R., Fiszbein, A. & Opler, L. A. The Positive and Negative Syndrome Scale

- 1 (PANSS) for schizophrenia. *Schizophr. Bull.* **13**, 261–276 (1987).
- 2 20. Peters, E., Joseph, S., Day, S. & Garety, P. Measuring delusional ideation: The 21-item
- 3 Peters et al. Delusions Inventory (PDI). *Schizophr. Bull.* **30**, 1005–1022 (2004).
- 4 21. Tanaka, S. C. *et al.* A multi-site, multi-disorder resting-state magnetic resonance
- 5 image database. *Sci. Data* **8**, 227 (2021).
- 6 22. Yamashita, A. *et al.* Generalizable brain network markers of major depressive
- 7 disorder across multiple imaging sites. *PLOS Biol.* **18**, e3000966 (2020).
- 8 23. Esteban, O. *et al.* fMRIPrep: A robust preprocessing pipeline for functional MRI. *Nat.*
- 9 *Methods* **16**, 111–116 (2019).
- 10 24. Dickie, E. W. *et al.* Ciftify: A framework for surface-based analysis of legacy MR
- 11 acquisitions. *NeuroImage* **197**, 818–826 (2019).
- 12 25. Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex. *Nature* **536**,
- 13 171–178 (2016).
- 14 26. Ji, J. L. *et al.* Mapping the human brain’s cortical-subcortical functional network
- 15 organization. *NeuroImage* **185**, 35–57 (2019).
- 16 27. Behzadi, Y., Restom, K., Liao, J. & Liu, T. T. A component based noise correction
- 17 method (CompCor) for BOLD and perfusion based fMRI. *NeuroImage* **37**, 90–101 (2007).
- 18 28. Satterthwaite, T. D. *et al.* An improved framework for confound regression and
- 19 filtering for control of motion artifact in the preprocessing of resting-state functional
- 20 connectivity data. *NeuroImage* **64**, 240–256 (2013).
- 21 29. Power, J. D. *et al.* Methods to detect, characterize, and remove motion artifact in
- 22 resting state fMRI. *NeuroImage* **84**, 320–341 (2014).
- 23 30. Fortin, J.-P. *et al.* Harmonization of multi-site diffusion tensor imaging data.
- 24 *NeuroImage* **161**, 149–170 (2017).
- 25 31. Fortin, J.-P. *et al.* Harmonization of cortical thickness measurements across scanners

- 1 and sites. *NeuroImage* **167**, 104–120 (2018).
- 2 32. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray
3 expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 4 33. Sherazi, S. W. A., Bae, J.-W. & Lee, J. Y. A soft voting ensemble classifier for early
5 prediction and diagnosis of occurrences of major adverse cardiovascular events for STEMI and
6 NSTEMI during 2-year follow-up in patients with acute coronary syndrome. *PLOS ONE* **16**,
7 e0249338 (2021).
- 8 34. Boser, B. E., Guyon, I. M. & Vapnik, V. N. A training algorithm for optimal margin
9 classifiers. in *Proceedings of the Fifth Annual Workshop on Computational Learning Theory*.
10 *Colt '92* 144–152 (ACM Press, Pittsburgh, Pennsylvania, United States, 1992).
11 doi:10.1145/130385.130401.
- 12 35. Tin Kam Ho. Random decision forests. in *Proceedings of 3rd International*
13 *Conference on Document Analysis and Recognition* vol. 1 278–282 (IEEE Comput. Soc. Press,
14 Montreal, Que., Canada, 1995).
- 15 36. Ke, G. *et al.* LightGBM: A Highly Efficient Gradient Boosting Decision Tree. 9.
- 16 37. Rumelhart, D. E., Hinton, G. E. & Williams, R. J. Learning Internal Representations
17 by Error Propagation. in *Readings in Cognitive Science* 399–421 (Elsevier, 1988).
18 doi:10.1016/B978-1-4832-1446-7.50035-2.
- 19 38. Roldán-Nofuentes, J. A. Compbdt: an R program to compare two binary diagnostic
20 tests subject to a paired design. *BMC Med. Res. Methodol.* **20**, 143 (2020).
- 21 39. Lincoln, T. M., Ziegler, M., Lüllmann, E., Müller, M. J. & Rief, W. Can delusions be
22 self-assessed? Concordance between self- and observer-rated delusions in schizophrenia.
23 *Psychiatry Res.* **178**, 249–254 (2010).
- 24 40. Balzan, R. P., Delfabbro, P. H., Galletly, C. A. & Woodward, T. S. Metacognitive
25 training for patients with schizophrenia: Preliminary evidence for a targeted, single-module

- 1 programme. *Aust. N. Z. J. Psychiatry* **48**, 1126–1136 (2014).
- 2 41. Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D.
3 Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for
4 schizophrenia. *Schizophr. Res.* **137**, 246–250 (2012).
- 5 42. McGorry, P. D., Killackey, E. & Yung, A. Early intervention in psychosis: Concepts,
6 evidence and future directions. *World Psychiatry* **7**, 148–156 (2008).
- 7 43. Newton, R. *et al.* Diverse definitions of the early course of schizophrenia—A targeted
8 literature review. *Npj Schizophr.* **4**, 21 (2018).
- 9 44. Leucht, S. *et al.* What does the PANSS mean? *Schizophr. Res.* **79**, 231–238 (2005).
- 10 45. Okada, G. *et al.* Verification of the brain network marker of major depressive disorder:
11 Test-retest reliability and anterograde generalization performance for newly acquired data. *J.*
12 *Affect. Disord.* **326**, 262–266 (2023).
- 13 46. Chan, R. C. K., Di, X., McAlonan, G. M. & Gong, Q. -y. Brain anatomical
14 abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: An activation
15 likelihood estimation meta-analysis of illness progression. *Schizophr. Bull.* **37**, 177–188
16 (2011).
- 17 47. Tu, P.-C., Hsieh, J.-C., Li, C.-T., Bai, Y.-M. & Su, T.-P. Cortico-striatal disconnection
18 within the cingulo-opercular network in schizophrenia revealed by intrinsic functional
19 connectivity analysis: A resting fMRI study. *NeuroImage* **59**, 238–247 (2012).
- 20 48. Li, S. *et al.* Dysconnectivity of multiple brain networks in schizophrenia: A
21 meta-analysis of resting-state functional connectivity. *Front. Psychiatry* **10**, 482 (2019).
- 22 49. Peters, S. K., Dunlop, K. & Downar, J. Cortico-striatal-thalamic loop circuits of the
23 salience network: A central pathway in psychiatric disease and treatment. *Front. Syst. Neurosci.*
24 **10**, (2016).
- 25 50. Cadena, E. J. *et al.* Cognitive control network dysconnectivity and response to

- 1 antipsychotic treatment in schizophrenia. *Schizophr. Res.* **204**, 262–270 (2019).
- 2 51. Anticevic, A. *et al.* Characterizing thalamo-cortical disturbances in schizophrenia and
3 bipolar illness. *Cereb. Cortex* **24**, 3116–3130 (2014).
- 4 52. Andreasen, N. C. The role of the thalamus in schizophrenia. *Can. J. Psychiatry* **42**,
5 27–33 (1997).
- 6 53. Wu, X. *et al.* Functional network connectivity alterations in schizophrenia and
7 depression. *Psychiatry Res. Neuroimaging* **263**, 113–120 (2017).
- 8 54. Koike, S. *et al.* Shared functional impairment in the prefrontal cortex affects symptom
9 severity across psychiatric disorders. *Psychol. Med.* **52**, 2661–70 (2020).
- 10 55. Jutla, A., Foss Feig, J. & Veenstra Vanderweele, J. Autism spectrum disorder and
11 schizophrenia: An updated conceptual review. *Autism Res.* **15**, 384–412 (2021).
- 12 56. Writing Committee for the Attention-Deficit/Hyperactivity Disorder *et al.* Virtual
13 Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. *JAMA*
14 *Psychiatry* **78**, 47 (2021).
- 15 57. Goodkind, M. *et al.* Identification of a common neurobiological substrate for mental
16 illness. *JAMA Psychiatry* **72**, 305 (2015).
- 17 58. Li, A. *et al.* A neuroimaging biomarker for striatal dysfunction in schizophrenia. *Nat.*
18 *Med.* **26**, 558–565 (2020).
- 19 59. Wang, D. *et al.* Individual-specific functional connectivity markers track dimensional
20 and categorical features of psychotic illness. *Mol. Psychiatry* **25**, 2119–2129 (2020).
- 21 60. Ferri, J. *et al.* Resting-state thalamic dysconnectivity in schizophrenia and
22 relationships with symptoms. *Psychol. Med.* **48**, 2492–2499 (2018).
- 23 61. Hoptman, M. J. *et al.* Decreased interhemispheric coordination in schizophrenia: A
24 resting state fMRI study. *Schizophr. Res.* **141**, 1–7 (2012).
- 25 62. Schröder, J., Wenz, F., Schad, L. R., Baudendistel, K. & Knopp, M. V. Sensorimotor

- 1 cortex and supplementary motor area changes in schizophrenia. A study with functional
2 magnetic resonance imaging. *Br. J. Psychiatry* **167**, 197–201 (1995).
- 3 63. Fountoulakis, K. N., Panagiotidis, P., Gonda, X., Kimiskidis, V. & Nimatoudis, I.
4 Neurological soft signs significantly differentiate schizophrenia patients from healthy controls.
5 *Acta Neuropsychiatr.* **30**, 97–105 (2018).
- 6 64. Leclerc, M. P., Regenbogen, C., Hamilton, R. H. & Habel, U. Some neuroanatomical
7 insights to impulsive aggression in schizophrenia. *Schizophr. Res.* **201**, 27–34 (2018).
- 8 65. Wong, T. Y. *et al.* Neural networks of aggression: ALE meta-analyses on trait and
9 elicited aggression. *Brain Struct. Funct.* **224**, 133–148 (2019).
- 10 66. Taylor, J. E. *et al.* Depressive symptoms reduce when dorsolateral prefrontal
11 cortex-precuneus connectivity normalizes after functional connectivity neurofeedback. *Sci.*
12 *Rep.* **12**, 2581 (2022).
- 13 67. Takamura, M. *et al.* Application of functional connectivity neurofeedback in patients
14 with treatment-resistant depression: A preliminary report. *J. Affect. Disord. Rep.* **14**, 100644
15 (2023).
- 16 68. Crossley, N. A. *et al.* Superior temporal lobe dysfunction and frontotemporal
17 dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. *Hum. Brain*
18 *Mapp.* **30**, 4129–4137 (2009).
- 19 69. Wen, K. *et al.* Cortical thickness abnormalities in patients with first episode psychosis:
20 a meta-analysis of psychoradiologic studies and replication in an independent sample.
21 *Psychoradiology* **1**, 185–198 (2021).

22

23

1 **FIGURE LEGENDS**

2 **Figure 1. Outline of the study**

3 This study was composed of two parts. **(I)** Constructing SSD classifier: Using the discovery
4 dataset, we processed rs-fMRI images into an FC matrix for each participant, which was then
5 inputted into machine learning (LASSO) to build SSD classifiers. We obtained the
6 classification performance through 10-fold CV and examined its external generalisability using
7 the validation dataset. ‘Important FCs’ were those that made the highest contribution to the
8 classification. To assess classifier specificity for SSD, we also applied the classifiers to other
9 mental disorders. We performed further analyses on another machine learning method (voting
10 classifiers) and on classification performance by disease severity. **(II)** Exploring
11 trait/state/staging markers of SSD: We investigated the different types of biomarkers inherent
12 in important FCs. First, we attempted to predict clinical scale scores using aggregated FCs.
13 Second, we searched for individual FCs associated with the state and/or disease stage. CV,
14 cross-validation; SSD, schizophrenia spectrum disorder; LASSO, least absolute shrinkage and
15 selection operator; rs-fMRI, resting-state functional magnetic resonance imaging; FC,
16 functional connectivity.

17

18 **Figure 2. Probability density curves based on LASSO classifiers**

19 **(a)** Results for all the sites combined in the discovery dataset. **(b)** Results for individual sites in
20 the discovery dataset. **(c)** Results for all the sites combined in the validation dataset. **(d)** Results
21 for individual sites in the validation dataset. As four sites in Hiroshima (COI, HKH, HRC, and
22 HUH) did not have any patients with SSD, these sites have a curve for HCs only. HC, healthy
23 control; SSD, schizophrenia spectrum disorder; AUC, area under the curve; MCC, Matthews’
24 correlation coefficient; LASSO, least absolute shrinkage and selection operator; COBRE,

1 Centre of Biomedical Research Excellence.

2

3 **Figure 3. Important FCs ($P < 0.05$) in diagnosis prediction by LASSO classifiers**

4 (a) Each node on the inner circle corresponds to an ROI. The line width of the FC shows how
5 many times it was selected by the classifiers, and the line colour denotes the direction to which
6 it contributes to the logistic regression model (red means that the higher the FC value is, the
7 more likely the classifier's output is to be SSD; blue means a lower FC value for a higher
8 likelihood of SSD). (b) The 47 important FCs were projected onto glass brains. The colours of
9 the ROIs in relation to each intrinsic brain network and the red/blue line colours correspond to
10 those in (a). (c) The mean FC values (Z-score, on the ordinate) of the 47 important FCs for the
11 HC and SSD groups are shown as a bar plot for the discovery and validation datasets. Error
12 bars represent standard error. The FC numbers on the abscissa correspond to those in (a) and
13 **Supplementary Table 4.** FC, functional connectivity; HC, healthy control; SSD,
14 schizophrenia spectrum disorder; ROI, region of interest; LASSO, least absolute shrinkage and
15 selection operator.

16

17 **Figure 4. Trait, state, and staging marker analyses**

18 (a, b) Prediction results of PDI total and PANSS total scores. The relationship between the
19 predicted scores (on the ordinate) and actual scores (on the abscissa) for the validation dataset
20 is shown in a scatter plot. The grey translucent band represents the 95% confidence interval of
21 the regression line. (a) PDI total scores. (b) PANSS total score. (c) Individual FCs associated
22 with disease stage. This heat map shows the results of the bootstrap method, where the number
23 in the colour bar indicates the number of times the FC was sorted into a category out of 1,000
24 iterations. n.s., not significant ($P \geq 0.05$ for all three explanatory variables or any of the
25 coefficients' signs were inconsistent with the average weight in LASSO classifiers); MAE,

- 1 mean absolute error; PDI, Peters et al. Delusion Inventory; PANSS, Positive and Negative
- 2 Syndrome Scale; FC, functional connectivity; LASSO, least absolute shrinkage and selection
- 3 operator.

1 TABLES

2 **Table 1. Demographics of the participants (HCs and patients with SSD)**

Site	Abbr.	HC			SSD			Total (HC and SSD)			
		Number	M/F	Age (mean±SD)	Number	M/F	Age (mean±SD)	Number	M/F	Age (mean±SD)	
Discovery dataset											
Kyoto University (Tim Trio)	KUT	223	127/96	33.4±13.2	61	32/29	40.7±13.2	284	159/125	35.1±13.2	
Showa University	SWA	101	86/15	31.4±7.9	19	15/4	42.7±8.4	120	101/19	30.7±9.5	
Centre of Innovation, Hiroshima University	COI	124	46/78	51.9±13.4	–	–	–	124	46/78	51.9±13.4	
University of Tokyo	UTO	169	77/92	35.7±17.5	36	24/12	23.3±10.3	205	101/104	34.9±16.5	
Summary		617	336/281	36.9±16.0	116	71/45	38.5±11.4	733	407/326	37.2±15.3	
Validation dataset											
Kyoto University (Trio)	KTT	72	44/28	28.7±9.4	48	23/25	37.8±9.4	120	67/53	32.4±10.4	
Kyoto University (Prisma)	KUP	11	7/4	35.0±8.5	18	11/7	40.2±12.9	29	18/11	38.2±11.6	
Hiroshima University Hospital	HUH	66	29/37	34.6±13.0	–	–	–	66	29/37	34.6±13.0	

Hiroshima Kajikawa Hospital	HKH	29	12/17	45.4±9.5		–	–	–		29	12/17	45.4±9.5
Hiroshima Research Centre	HRC	49	13/36	41.7±11.7		–	–	–		49	13/36	41.7±11.7
Centre of Biomedical Research Excellence	COBRE	73	50/23	35.7±11.6		67	57/10	37.4±13.8		140	107/33	36.6±12.7
Taipei Medical University	TMU	29	26/3	31.4±5.0		32	23/9	35.3±6.1		61	49/12	33.4±5.9
Johns Hopkins University	JHU	75	37/38	24.4±4.1		33	23/10	22.5±4.7		108	60/48	23.8±4.4
Summary		404	218/186	32.3±11.6		198	137/61	34.9±11.9		602	355/247	33.8±11.7

- 1
- 2 The distributions of age and sex were not significantly different between the HC and SSD groups in the discovery dataset ($P>0.05$). In the
- 3 validation dataset, the age distribution was not significantly different ($P>0.05$); however, the sex distribution was significantly different ($P<0.05$).
- 4 Abbr., abbreviations; HC, healthy control; SSD, schizophrenia spectrum disorder; SD, standard deviation.

1 **Table 2. Individual FCs significantly associated with PANSS factorial scores**

Score conversion	Three-factor model		Five-factor model				
	Positive	Negative	Positive	Negative	Disorganised	Excited	Depressed
1. Min-max transformation	#41: R.6a and R.PoII #45: R.TPOJ1 and R.Thalamus	#1: L.3b and L.1 #8: L.1 and R.3b	#5: L.5L and R.Cereb #42: R.i6-8 and R.PeEc #45: R.TPOJ1 and R.Thalamus			#17: L.MI and R.Putamen #18: L.FOP1 and R.Putamen #41: R.6a and R.PoII #43: R.FOP4 and R.Putamen	#27: R.RSC and R.SFL #28: R.POS2 and R.SFL
2. Binarisation	#33: R.6ma and R.Cereb	#2: L.POS2 and R.SFL	#3: L.PCV and L.POS1	#8: L.1 and R.3b	#8: L.1 and R.3b	#2: L.POS2 and R.SFL	#27: R.RSC and R.SFL

	<p>#45: R.TPOJ1 and R.Thalamus</p>	<p>#8: L.1 and R.3b</p> <p>#28: R.POS2 and R.SFL</p>				<p>#14: L.IFSa and R.AVI</p> <p>#18: L.FOP1 and R.Putamen</p> <p>#38: R.p32pr and R.Putamen</p> <p>#41: R.6a and R.PoII</p> <p>#43: R.FOP4 and R.Putamen</p> <p>#44: R.FOP1 and R.Putamen</p>	
--	--	--	--	--	--	---	--

1

2 Using multiple regression analyses, the FCs significantly associated with each PANSS factor were identified. When the coefficient for the

3 factor was positive, the FC is coloured red, and when it was negative, the FC is coloured blue. ‘Pure state markers’ (the case in which the


- 1 explanatory variable of the PANSS factor was solely associated with the FC) are highlighted in bold letters. The ROIs described here are from
- 2 Glasser's parcellation. FC, functional connectivity; PANSS, Positive and Negative Syndrome Scale; ROI, region of interest.

I. Developing Clinically Applicable SSD Classifiers

Concerns about rsfMRI biomarkers


1. Inadequate accuracy
2. Insufficient generalisability
3. Across-scan variability
4. Lack of disease specificity

Aim: To overcome these by the methodology below



II. Exploring Trait / State / Staging markers of SSD

- Trait** Diagnosis, delusional tendency etc.
- State** Symptom (subject to change)
- Stage** e.g. early, chronic




Results for LASSO Classifiers

Discovery dataset


a

All sites



b


Individual sites



Validation dataset

c

All sites



d

Individual sites

